Company Overview and News

 
Select Sands Announces Temporary Furlough at Sandtown

2018-10-15 globenewswire
VANCOUVER, B.C., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSXV: SNS | OTCQX: SLSDF) announced today that it has placed 26 employees at its Arkansas operations on temporary furlough until further notice. This necessary step results from the current industry-wide market disruption, which has impacted demand for Select Sands' Northern White frac sand. Shipments and limited production continue, while the Company continues to pursue additional opportunities.
CLICF SLSDF SNS

2
Select Sands Announces Conclusion of Supply Agreement with Liberty Oilfield Services, LLC

2018-09-04 globenewswire
VANCOUVER, British Columbia, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSXV: SNS | OTCQX: SLSDF), announces that it has received notice from Liberty Oilfield Services, LLC (“Liberty”) of Liberty’s intention to terminate its current frac sand supply agreement (the “Agreement”) with Select Sands. It is anticipated that such termination will take effect in late November.
CLICF SLSDF LBRT SNS

 
Select Sands Reports Record Results for the Second Quarter 2018

2018-08-13 globenewswire
-- Strong Demand and Continued Logistics Enhancements Drive Sale of ~165K Tons of Frac Sand -- -- Records 31% Margin on Adjusted EBITDA of $2.9 Million – 255% Higher than $0.8 Million in Q1 2018 -- -- Significant Progress on Expansion Project to Boost Production Capacity by 67% to 1 Million Tons Per Year --
CLICF SLSDF SNS

1
Select Sands Corp. - Mining For Value

2018-07-24 seekingalpha - 1
Select Sands represents an opportunity to invest in a frac-sand producer with a distinct geographical advantage trading at a fraction of what the company would be worth to an acquirer.
CLICF SLSDF UNP SNS SND SLCA HCLP

 
Select Sands Files Early Warning Report

2018-07-04 globenewswire
VANCOUVER, British Columbia, July 04, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSX VENTURE:SNS) (OTC:CLICF) announced today that it has filed an early warning report in respect of its acquisition of 2,635,400 units of Comstock Metals Ltd. ("Comstock") pursuant to the non-brokered private placement completed by Comstock on July 3, 2018. Each unit is comprised of one common share in the capital of Comstock and one common share purchase warrant of Comstock (a "Warrant").
CLICF CMMMF SLSDF CSL SNS CMMMD

 
Select Sands Reports First Quarter 2018 Results

2018-05-17 globenewswire
Improved Margins Drove Adjusted EBITDA Higher in Q1 2018 by More than 300% from Q4 2017
CLICF SLSDF SNS

 
Select Sands To Release Q1 2018 Financial Results May 17, 2018 and Schedules Conference Call

2018-05-10 globenewswire
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. (“Select Sands” or the “Company”) (TSXV:SNS) (OTC:SLSDF) will release financial and operational results for the first quarter of 2018 on Thursday May 17th after the market closes, and will host a conference call on Friday, May 18th at 11:00 AM EDT (8:00 AM PDT).
CLICF SLSDF SNS

 
Select Sands Appoints Daniel A. Gillett as Chairman of the Board

2018-04-27 globenewswire
VANCOUVER, British Columbia, April 27, 2018 (GLOBE NEWSWIRE) -- The board of directors of Select Sands Corp. ("Select Sands" or the "Company") (TSXV:SNS) (OTCQX:SLSDF) is pleased to announce the appointment of Mr. Daniel A. Gillett as Chairman of the Board.
CLICF SLSDF SNS

 
Select Sands Announces Grant of Options

2018-04-13 globenewswire
VANCOUVER, British Columbia , April 13, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSXV:SNS) (OTC:SLSDF) today announced that certain officers and directors have been issued an aggregate of 2,400,000 options pursuant to the Company’s option plan. Each option is exercisable into one common share at an exercise price of Cdn$0.39 at any time on or before the fifth anniversary of its issuance.
CLICF SLSDF SNS

 
Select Sands Reports Full Year and Fourth Quarter 2017 Results

2018-04-11 globenewswire
Frac and Industrial Sand Sales Volumes Grew at 71% Quarterly Rate from Q1 to Q4, With Stronger Pricing Seen Throughout the Year
CLICF SLSDF SNS

 
Select Sands Exercises Purchase Option to Begin Capacity Expansion

2018-04-10 globenewswire
VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSXV:SNS) (OTCQX:SLSDF) is pleased to announce the Company has exercised its option to purchase a 223-acre property located in Independence County, Arkansas (the “Independence Property”) to serve as a platform to support the Company’s long-term operational and capacity expansion initiatives.
CLICF SLSDF SNS

 
Select Sands Corp. to Release 2017 Year-End Financials on April 11, 2018 and Host Investor Conference Call

2018-03-27 globenewswire
VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSXV:SNS) (OTCQX:SLSDF) is pleased to announce that it will be releasing its fourth quarter and full 2017 year end results on Wednesday, April 11, 2018 before market open. A conference call to discuss these results will be held on the same day at 8:45 AM EST (5:45 AM PST).
CLICF SLSDF SNS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:SNS / Select Sands Corp on message board site Silicon Investor.

Image Sensing Systems ISNS Image Sensing Systems ISNS Image Sensing Systems ISNS Sunesis Pharmaceuticals (SNSS) Sunesis Pharmaceuticals (SNSS) Sunesis Pharmaceuticals (SNSS)
HSNS- The next Real Networks HSNS- The next Real Networks HSNS- The next Real Networks HSNS ---------- READY TO OPEN UP !!! HSNS ---------- READY TO OPEN UP !!! HSNS ---------- READY TO OPEN UP !!!
SNS - Sunstrand Corp SNS - Sunstrand Corp SNS - Sunstrand Corp